SEC Form 4 · accession 0001127602-16-060081
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Aug 9, 2016
Accepted (ET)
Aug 11, 2016 · 1:53 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 9, 2016 | S | 14,577 | $4.43 | D | 130,051 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $4.18 to $5.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.